The 5-Gene-Multiplex Set cfDNA in Plasma is an advanced product designed for use in molecular diagnostics. It includes five key mutations found in the BRAF, KRAS, PIK3CA, AKT1, and ERBB2 genes, all of which are highly relevant both diagnostically and therapeutically. These mutations are known to play a crucial role in the progression of various types of tumors, including breast carcinoma, colorectal carcinoma, melanoma, non-small cell lung carcinoma, small cell lung carcinoma, prostate carcinoma, lymphoma, head and neck carcinoma, hepatocellular carcinoma, multiple myeloma, pancreatic adenocarcinoma, ovarian carcinoma, bladder carcinoma, bile duct carcinoma, and several others.

The 5-Gene-Multiplex Set cfDNA in Plasma is primarily intended for liquid biopsy assays in diagnostic labs and R&Ddepartments. It provides a standardized allelic frequency range of 0%, 0.1%, 1%, and 5% that can be used for the validation and development of diagnostic kits. The product uses highly characterized human cfDNA derived from cell lines to ensure high-quality results. This set consists of four individual products (SID-000002, SID-000088, SID-000089, and SID-000090) and can be utilized for both qualitative and quantitative validation of laboratory processes.

In summary, the 5-Gene-Multiplex Set cfDNA in Plasma is an essential tool for improving the accuracy and efficiency of genetic diagnostics and cancer research. It plays a vital role in the development of liquid biopsy technologies, which offer non-invasive alternatives for cancer detection and monitoring.